BeStock  
Stocks › Biotechnology › GLUE

Monte Rosa Therapeutics GLUE

US equityMarket cap rank #3343Biotechnology
$10.17 +$0.30 (+3.04%)
Pre-market · Oct 8, 7:50 am ET · After hours $10.00 -1.67%
Open$9.84
Prev close$9.87
Day range$9.68 – $10.75
Volume2.08M
Market cap$867.64M
P/E (TTM)–
Dividend yield–

Valuation

Multiples measured against the stock's own five-year history

Price / earnings-5.8x
CheapRich

Near the bottom of its 5-year range · 12th percentile, 5-year average 2.7x

Price / book1.8x
CheapRich

Above its usual level · 64th percentile, 5-year average 2.1x

#2711 of 5317 stocks by PB (1 = cheapest)

Price / sales30.2x
CheapRich

Above its usual level · 79th percentile, 5-year average 21.7x

#4762 of 5146 stocks by PS (1 = cheapest)

P/E over five years

-52x-7x38x83xOct '21Apr '24Oct '26

Dashed line is the 5-year average; the shaded band is one standard deviation either side.

Morningstar fair value estimate

Fair value$10.38
Price vs. fair value-2.1%Close to the estimate
Star rating★★★☆☆
Economic moatNone
UncertaintyVery High
MultipleCurrentForward5y averagePercentile vs. own historyIndustry rank
PB 1.78 – 2.06 64% (pricier than usual) #2711 of 5317 (1 = cheapest)
PE -5.81 -4.62 2.69 12% (cheaper than usual) –
PS 30.20 13.54 21.69 79% (pricier than usual) #4762 of 5146 (1 = cheapest)

Percentile is against this stock’s own 5-year valuation range: higher means it’s trading rich relative to its own history, lower means cheap relative to its own history — it is not a comparison against other companies. Forward multiples use consensus estimates for the next twelve months; a forward multiple below the current one usually signals analysts expect earnings to grow.

Morningstar view

Star rating★★★
Fair value estimate$10.38
Economic moatNone
UncertaintyVery High

Discussion

No comments yet — be the first to weigh in on GLUE.

Leave a comment

Scroll to Top